Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

Journal of Hypertension

Volumn 23, Issue 2, 2005, Pages 417-426

  Wood, Jeanette M ^a   Schnell, Christian R ^a   Cumin, Frederic ^a   Menard, Joël ^b   Webb, Randy L ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b INSERM   (France)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Blood pressure; Hypertension; Marmoset; Renin; Telemetry

Indexed keywords

ALISKIREN; BENAZEPRIL; REMIKIREN; RENIN INHIBITOR; SEROTONIN 1 ANTAGONIST; VALSARTAN; ZANKIREN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEART RATE; HYPERTENSION; MALE; MARMOSET; MOLECULAR MODEL; NONHUMAN; OSMOTIC MINIPUMP; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY;

EID: 14044271546     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200502000-00025     Document Type: Article

References (39)

1. Hackenthal E, Hackenthal R, Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes. Biochim Biophys Acta 1978; 522:574-588.
2. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89:493-498.
3. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues A review of experimental evidence. Circulation 1994; 89:458-470.
4. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
5. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction - a matter of dose. N Engl J Med 2003; 349:1963-1965.
6. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
7. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
9. Wood JM, Stanton JL, Hofbauer KG. Inhibitors of renin as potential therapeutic agents. J Enzyme Inhib 1987; 1:169-185.
10. Corvol P, Menard J. Renin inhibition: immunological procedures and renin inhibitor peptides. Fundam Clin Pharmacol 1989; 3:347-362.
11. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106:439-453.
12. Stanton A. Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4:6-10.
13. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000; 7:493-504.
14. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308:698-705.
15. Himmelmann A, Bergbrant A, Svensson A, Hansson L, Aurell M. Remikiren (Ro 42-5892) - an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am J Hypertens 1996; 9:517-522.
16. Menard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 1995; 91:330-338.
17. Michel JB, Wood J, Hofbauer K, Corvol P, Menard J, Blood pressure effects of renin inhibition by human renin antiserum in normotensive marmosets, Am J Physiol 1984; 246:F309-F316.
18. Schnell CR, Wood JM. Measurement of blood pressure and heart rate by telemetry in conscious, unrestrained marmosets. Am J Physiol 1993; 264:H1509-H1516.
19. Poulsen K, Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974; 39:816-825.
20. Cumin F, de Gasparo M, Wood JM, Schnell C, Frueh F, Graf P. Assays to measure nanomolar levels of the renin inhibitor CGP 38 560 in plasma. Hypertension 1989; 14:379-384.
21. Bazil MK, Krulan C, Webb RL. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 22:897-905.
22. Webb RL, Navarrete AE, Davis S, de Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J Hypertens 1998; 16:843-852.
23. Wood JM, Jobber RA, Baum HP, Hofbauer KG. Comparison of chronic inhibition of renin and converting enzyme in the marmoset. Clin Exp Hypertens A 1987; 9:337-343.
24. Wood JM, Criscione L, de Gasparo M, Buhlmayer P, Rueger H, Stanton JL, et al. CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. J Cardiovasc Pharmacol 1989; 14:221-226.
25. Fischli W, Clozel JP, el Amrani K, Wostl W, Neidhart W, Stadier H, et al. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension 1991; 18:22-31.
26. de Gaspard M, Cumin F, Nussberger J, Guyenne TT, Wood JM, Menard J. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol 1989; 27:587-596.
27. Derkx FH, van den Meiracker AH, Fischli W, Admiraal PJ, Man in't Veld AJ, van Brummelen P, et al. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact. Am J Hypertens 1991; 4:602-609.
28. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:E1-E8.
29. Classman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. J Cardiovasc Pharmacol 1990; 16(suppl 4):S76-S81.
30. Azizi M, Guyene TT, Chatellier G, Menard J. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1994; 12:419-427.
31. Neutel JM, Luther RR, Boger RS, Weber MA. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J 1991; 122:1094-1100.
32. Fossa AA, Weinberg LJ, Barber RL, Rauch AL, Nocerini MR, Murphy WR, et al. Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol 1992; 20:75-82.
33. Fossa A, DePasquale M, Ringer L. Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin- converting enzyme inhibitor with an angiotensin II receptor antagonist. Drug Dev Res 1994; 33:422-428.
34. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29:634-640.
35. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41:31-36.
36. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002; 71:68-76.
37. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42:1137-1143.
38. el Amrani Al, Menard J, Gonzales MF, Michel JB. Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol 1993; 22:231-239.
39. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, et al. Responses to converting enzyme and renin inhibition Role of angiotensin II in humans. Hypertension 1994; 23:44-51.